当代医学
噹代醫學
당대의학
CHINA CONTEMPORARY MEDICINE
2014年
6期
6-7
,共2页
古志红%邵淑丽%李波%孙青山
古誌紅%邵淑麗%李波%孫青山
고지홍%소숙려%리파%손청산
树突状细胞%顺铂%肿瘤免疫%卵巢癌
樹突狀細胞%順鉑%腫瘤免疫%卵巢癌
수돌상세포%순박%종류면역%란소암
Dendritic cells%Cisplatin%Tumor immunity%Ovarian cancer
目的:探讨用顺铂(DDP)诱导卵巢癌细胞株(SKOV 3)获得的肿瘤细胞裂解物以致敏树突状细胞(dendritic cells,DCs)诱导的CTL对肿瘤细胞的杀伤作用。方法分离健康者外周血单个核细胞,培养DC,分为三组。顺铂组:用顺铂诱导卵巢癌细胞株获得细胞裂解物致敏DC;冻融组:用冻融法获得细胞裂解物致敏DC;空白组:不做任何处理。成熟的DC与T细胞混合培养获得特异性细胞毒性T淋巴细胞(cytotoxic T lymphocyte,CTL)。流式细胞仪(flow cytometry,FCM)检测三组DC表型,CTL亚群比例,MTT检测CTL对SKOV3的杀伤效果。结果顺铂组DC的分子表面标志CD 86、CD 40表达分别为(76.35±3.99)%、(71.20±6.86)%,显著高于空白组(P<0.05),而与冻融组相比差异无统计学意义;两组DC诱导的特异性CTL,其亚群CD 8+T、CD 4+T比值[(80.42±4.61)%、(9.55±2.24)%]明显著于空白组(P<0.05);顺铂组诱导的CTL对SKOV3的杀伤率随着E/T比例(20∶1,40∶1,80∶1)的增加而逐步渐增高,杀伤率[(45.66±3.16)%、(50.16±3.44)%、(58.82±4.06)%]显著高于冻融组[(39.71±4.77)%、(47.00±4.02)%、(53.76±4.78)%]与空白组[(37.94±3.74)%、(41.11±5.04)%、(48.08±3.77)%]。结论 DDP诱导SKOV3来获得的肿瘤裂解物致敏DC能有效激活抗肿瘤免疫反应,提示化疗与生物治疗联合治疗可能是治疗卵巢癌潜在有效的方法。
目的:探討用順鉑(DDP)誘導卵巢癌細胞株(SKOV 3)穫得的腫瘤細胞裂解物以緻敏樹突狀細胞(dendritic cells,DCs)誘導的CTL對腫瘤細胞的殺傷作用。方法分離健康者外週血單箇覈細胞,培養DC,分為三組。順鉑組:用順鉑誘導卵巢癌細胞株穫得細胞裂解物緻敏DC;凍融組:用凍融法穫得細胞裂解物緻敏DC;空白組:不做任何處理。成熟的DC與T細胞混閤培養穫得特異性細胞毒性T淋巴細胞(cytotoxic T lymphocyte,CTL)。流式細胞儀(flow cytometry,FCM)檢測三組DC錶型,CTL亞群比例,MTT檢測CTL對SKOV3的殺傷效果。結果順鉑組DC的分子錶麵標誌CD 86、CD 40錶達分彆為(76.35±3.99)%、(71.20±6.86)%,顯著高于空白組(P<0.05),而與凍融組相比差異無統計學意義;兩組DC誘導的特異性CTL,其亞群CD 8+T、CD 4+T比值[(80.42±4.61)%、(9.55±2.24)%]明顯著于空白組(P<0.05);順鉑組誘導的CTL對SKOV3的殺傷率隨著E/T比例(20∶1,40∶1,80∶1)的增加而逐步漸增高,殺傷率[(45.66±3.16)%、(50.16±3.44)%、(58.82±4.06)%]顯著高于凍融組[(39.71±4.77)%、(47.00±4.02)%、(53.76±4.78)%]與空白組[(37.94±3.74)%、(41.11±5.04)%、(48.08±3.77)%]。結論 DDP誘導SKOV3來穫得的腫瘤裂解物緻敏DC能有效激活抗腫瘤免疫反應,提示化療與生物治療聯閤治療可能是治療卵巢癌潛在有效的方法。
목적:탐토용순박(DDP)유도란소암세포주(SKOV 3)획득적종류세포렬해물이치민수돌상세포(dendritic cells,DCs)유도적CTL대종류세포적살상작용。방법분리건강자외주혈단개핵세포,배양DC,분위삼조。순박조:용순박유도란소암세포주획득세포렬해물치민DC;동융조:용동융법획득세포렬해물치민DC;공백조:불주임하처리。성숙적DC여T세포혼합배양획득특이성세포독성T림파세포(cytotoxic T lymphocyte,CTL)。류식세포의(flow cytometry,FCM)검측삼조DC표형,CTL아군비례,MTT검측CTL대SKOV3적살상효과。결과순박조DC적분자표면표지CD 86、CD 40표체분별위(76.35±3.99)%、(71.20±6.86)%,현저고우공백조(P<0.05),이여동융조상비차이무통계학의의;량조DC유도적특이성CTL,기아군CD 8+T、CD 4+T비치[(80.42±4.61)%、(9.55±2.24)%]명현저우공백조(P<0.05);순박조유도적CTL대SKOV3적살상솔수착E/T비례(20∶1,40∶1,80∶1)적증가이축보점증고,살상솔[(45.66±3.16)%、(50.16±3.44)%、(58.82±4.06)%]현저고우동융조[(39.71±4.77)%、(47.00±4.02)%、(53.76±4.78)%]여공백조[(37.94±3.74)%、(41.11±5.04)%、(48.08±3.77)%]。결론 DDP유도SKOV3래획득적종류렬해물치민DC능유효격활항종류면역반응,제시화료여생물치료연합치료가능시치료란소암잠재유효적방법。
Objective To discuss the killing effect of CTL induced by dendritic cells (DCs) sensitized by tumor cell lysate which was acquired by Cisplatin inducing ovarian cancer cells (SKOV 3) to tumor cell. Methods Mononuclear cells of peripheral blood of healthy pepole was separated and the DC was cultivated. There was three groups. Cisplatin group:DC was sensitized by tumor cell lysate which was acquired by Cisplatin inducing ovarian cancer cells. Freeze-thaw groups:DC was sensitized by tumor cell lysate which was obtained by freezing and thawing method. Blank group:There was no any processing. Mature DC and T cells were mixed and cultivated to get cytotoxic T lymphocyte(CTL). DC phenotype of three groups and CTL subgroup ratio were detected by Flow cytometry (FCM). The killing effect of CTL to SKOV 3 was tested by MTT. Results The expression of CD 86 and CD 40 of molecular surface marks of DC in Cisplatin group were (76.35±3.99)%and(71.20±6.86)%and it was significantly higher than that of blank group(P<0.05), while there was no statistical difference to freeze-thaw group. The ratio of CD 8+T andCD 4+T of subgroups of specific CTL induced by two sets of DC were (80.42±4.61)%and (9.55±2.24)%, which was significantly higher than the blank group (P<0.05). The kill rate of CTL induced by Cisplatin group to SKOV 3 gradually increased with the increase of E/T ratio (20∶1, 40∶1, 80∶1) and the kill rate [(45.66±3.16)%、(50.16±3.44)%、(58.82±4.06)%] was significantly higher than the freezing and thawing group [(39.71±4.77)%、(47.00±4.02)%、(53.76±4.78)%] and blank group[(37.94±3.74)%、(41.11±5.04)%、(48.08±3.77)%]. Conclusion DC sensitized by tumor cell lysate induced by Cisplatin which was acquired by DDP inducing ovarian cancer cells (SKOV 3) can effectively activate anti-tumor immune response. TIP:The combination therapy of chemotherapy and biological therapy biological combined treatment may be a potential effective method for treatment of ovarian cancer.